Title

1

- 2 Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein
- 3 profiles in inflammatory bowel disease

Short title 4

5 Longitudinal biomarker clustering in inflammatory bowel disease

Authors 6

- Nathan Constantine-Cooke*1,2, Marie Vibeke Vestergaard*3, Nikolas Plevris1,4, Karla 7
- Monterrubio-Gómez^{1,2}, Clara Ramos Belinchón^{1,4}, Solomon Ong⁴, Alexander T. 8
- 9 Elford^{4,5}, Beatriz Gros^{4,6}, Aleksejs Sazonovs³, Gareth-Rhys Jones^{4,7}, Tine Jess^{†3,8},
- 10 Catalina A. Vallejos^{† 2}, and Charlie W. Lees^{† 1,3,4}
- 11 * Joint first authors,
- 12 † Joint senior authors
- 13 Affiliations
- 14 1. Centre for Genomic and Experimental Medicine. Institute of Genetics and 15 Cancer, University of Edinburgh, Edinburgh, UK
- 16 2. MRC Human Genetics Unit, Institute of Genetics and Cancer, University of 17 Edinburgh, Edinburgh, UK
- 18 3. Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT,
- 19 Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark
- 20 4. Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK
- 21 5. Faculty of Medicine, The University of Melbourne, Melbourne, Australia
- 22 6. Reina Sofía University Hospital, Gastroenterology and Hepatology. IMIBIC.
- 23 University of Cordoba, Cordoba, Spain
- 24 7. Centre for Inflammation Research, The Queen's Medical Research Institute, 25 University of Edinburgh, Edinburgh, UK
- 8. Department of Gastroenterology & Hepatology, Aalborg University Hospital, 26 27 Aalborg, Denmark

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

28

29

36

Background

- 30 Crohn's disease (CD) and ulcerative colitis (UC) are highly heterogeneous, dynamic
- 31 and unpredictable, with a marked disconnect between symptoms and intestinal
- 32 inflammation. Attempts to classify inflammatory bowel disease (IBD) subphenotypes
- to inform clinical decision making have been limited. We aimed to describe the latent 33
- 34 disease heterogeneity by modelling routinely collected faecal calprotectin (FC) and
- 35 CRP data, describing dynamic longitudinal inflammatory patterns in IBD.

Methods

- 37 In this longitudinal study, we analysed patient-level post-diagnosis measurements of
- 38 FC and CRP in two European cohorts. Latent class mixed models were used to cluster
- 39 individuals with similar longitudinal profiles. Associations between cluster assignment
- 40 and baseline characteristics were quantified using multinomial logistic regression.
- 41 Differences in advanced therapy use across clusters were also explored. Finally, we
- 42 considered uncertainty in cluster assignments with respect to follow-up length and the
- 43 overlap between FC and CRP clusters. We included 1036 patients in the FC discovery
- 44 analysis (Lothian) with a total of 10545 FC observations (median 9 per subject, IQR
- 45 6-13), and 7880 patients in the replication (Denmark). The CRP discovery analysis
- 46 consisted of 1838 patients with 49364 measurements (median 20 per subject: IQR
- 47 10–36), with 10041 patients in the replication cohort.

Findings

- 49 Eight distinct clusters of inflammatory behaviour over time were identified in the FC
- 50 and CRP analysis for the Scottish cohort. This model was then applied to the Danish
- 51 replication cohort, with similar patterns observed in both the Scottish and Danish
- 52 populations. The clusters, FC1-8 and CRP1-8, were ordered from the lowest
- 53 cumulative inflammatory burden to the highest. The clusters included groups with high
- 54 diagnostic levels of inflammation which rapidly normalised, groups where high
- 55 inflammation levels persisted throughout the full seven years of observation, and a
- 56 series of intermediates including delayed remitters and relapsing remitters.

CD and UC patients were unevenly distributed across the clusters. In UC, male sex was associated with the poorest prognostic cluster (FC8). The use and timing of advanced therapy was associated with cluster assignment, with the highest use of early advanced therapy in FC1. Of note, FC8 and CRP8 captured consistently high patterns of inflammation despite a high proportion of patients receiving advanced therapy, particularly for CD individuals. We observed that uncertainty in cluster assignments was higher for individuals with short longitudinal follow-up, particularly between clusters capturing similar earlier inflammation patterns. There was broadly poor agreement between FC and CRP clusters in keeping with the need to monitor both in clinical practice.

Interpretation

57

58

59

60

61

62

63

64

65

66

- 68 Distinct patterns of inflammatory behaviour over time are evident in patients with IBD.
- 69 Cluster assignment is associated with disease type and both the use and timing of
- 70 advanced therapy. These data pave the way for a deeper understanding of disease
- 71 heterogeneity in IBD and enhanced patient stratification in the clinic.

Introduction

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98 99

100

101

102

103

104

Inflammatory bowel disease (IBD), an umbrella term for Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU), has a prevalence of almost 1% in the UK.^{1,2} IBD is characterised by chronic relapsing and remitting inflammation of the gastrointestinal (GI) tract that confers a host of debilitating symptoms, negatively impacting quality of life.^{3,4} Studies have clearly demonstrated that uncontrolled GI tract inflammation increases the risk of disease progression and complications including colorectal cancer.⁵ stricturing/penetrating complications, and surgery.^{6,7} However, IBD is highly heterogeneous with respect to symptoms, inflammatory burden, treatment response, and long-term outcomes.

Current IBD classification methods are mostly based on historic nomenclature which utilise baseline phenotypic characteristics and do not take into account the dynamic and unpredictable nature of the disease. Attempts at developing prediction tools to identify high risk patients have been made but again use static clinical parameters, dismissing the changing nature of the disease.8 Furthermore, they do not take into account the influence of other factors, such as advanced therapy timing, on the disease course. In the wake of the increasing prevalence of IBD and associated healthcare burden.9 new methods to characterise the dynamic disease course and help identify at-risk individuals who require aggressive therapy with close monitoring versus those that need less intense input are essential.

The original IBSEN studies provided the first data on the clinical course of patients with UC and CD during the first 10-years of diagnosis. 10,11 However, these data were predicated on predefined disease patterns, rather than being data driven, utilising symptoms alone. It is now widely accepted that there is a clear disconnect between inflammation and symptoms in IBD.12 It is therefore imperative characterisations of disease course include objective parameters of inflammation.

C-reactive protein (CRP) and faecal calprotectin (FC) are well established tools for monitoring patients with IBD, but are typically interpreted in terms of the most recent measurement or short-term trends. Interrogation of long-term trends of inflammation could greatly assist clinical decision making and improve prediction of future events.

Moreover, modelling inflammatory behaviour over time might be a key tool for characterising the largely unexplained heterogeneity seen in IBD, and provide new tools for disease sub-phenotyping beyond the current Montreal classification.¹³

In this study, we aimed to 1) identify groups of IBD patients with similar longitudinal patterns of inflammation, 2) determine if these groupings were associated with age. sex, IBD type, Montreal classification, or therapy, and 3) explore whether subjects with similar longitudinal FC profiles also share similar CRP profiles. To assess the robustness of our findings, we perform the analysis separately in two population-level cohorts, one covering the NHS Lothian health board in Scotland and one national-level registry in Denmark.

Methods

Ethics

105

106

107

108

109

110

111

112

113

114

115

116

117

124

128

- 118 Usage of the Scottish dataset was approved by the local Caldicott Guardian (Project
- 119 ID: CRD18002, registered NHS Lothian information asset #IAR-954). In Denmark,
- 120 studies based on registry data alone are not required to obtain permission from the
- 121 regional ethics committees as confirmed by The Central Denmark Region Committees
- 122 on Health Research Ethics (legislation: 1–10–72-148-19). Patients or the public were
- 123 not involved in the design, conduct, reporting or dissemination plans of our research.

Study design

- 125 This was a cohort study carried out separately in two population-level cohorts, based
- 126 in Scotland and Denmark, respectively. Detailed definitions for each cohort are
- 127 provided in Supplementary Note 1.
- 129 In Scotland, patients with a confirmed diagnosis of IBD (Lennard-Jones criteria)¹⁴ were
- 130 followed up for a period of seven years from the date of diagnosis. Baseline phenotype
- 131 data (sex, age at diagnosis, IBD type, date of diagnosis) were obtained from the
- 132 Lothian IBD registry (LIBDR), a retrospective cohort of patients receiving IBD care in
- 133 Lothian, Scotland. The LIBDR is estimated to have identified 94.3% of all IBD patients

in the area. Using a population-level cohort reduces potential biases due to recruitment.¹⁵ When available, additional phenotyping was extracted by the clinical team from electronic health records (TrakCare; InterSystems, Cambridge, MA). This includes smoking and Montreal classification for disease location, behaviour and extent, all recorded at the time of diagnosis. Data on prescribing of all advanced therapies, including start/stop dates, were extracted from TrakCare and NHS Lothian pharmacy databases. Primary care prescribing data were not available.

In Denmark, patients with IBD were identified from national health registries using a methodology previously described by Agrawal et al. 16 Briefly, patients were required to have at least two IBD-related hospital interactions within a period of two years. All Danish residents are assigned a personal identification number which can be used to link interactions across the healthcare system. Montreal classification and smoking status were not available for the Danish cohort. However, this cohort had data on all redeemed primary care prescriptions for corticosteroid and immunosuppressants, in addition to advanced therapy prescribing.

Inclusion/exclusion criteria

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

In the LIBDR, subjects were required to have a confirmed diagnosis of IBD at any age and receive secondary care for their condition from the NHS Lothian health board. Only subjects with a recorded date of IBD diagnosis between 2005 and 2019 were included. The lower bound for this criteria was established as FC testing was not routinely performed prior to this date. The upper bound ensured subjects had the possibility of at least five years of follow-up at the time of data extraction. In the Danish cohort, subjects were required to have a date of diagnosis between January 2015 and September 2022. The lower bound was set based on when the Danish nationwide Register of Laboratory Results for Research became nationwide. The upper bound was set based on data availability.

In both cohorts, the following criteria were separately applied to longitudinal FC and CRP measurements. Subjects were required to have a diagnostic measurement (± three months of diagnosis, Figures S1, S2) and have a further two observations available within the follow up periods of five and seven years for the Danish and LIBDR

cohorts respectively. If any biomarker measurements were observed within three months prior to the recorded diagnosis date, measurements were realigned with respect to diagnosis (Figure S3). Only non-censored observations were considered in this calculation for FC. For CRP, this filtering was applied after preprocessing (see "Longitudinal measurements and preprocessing" section), and subjects with constant biomarker measurements over time were excluded.

Statistical analysis

Cohort description

166

167

168

169

170

171

172

173

187

- 174 Continuous variables were summarised as their median and interguartile range (IQR).
- 175 Categorical variables were summarised as counts and percentages.
- 176 Longitudinal measurements and preprocessing
- 177 For the LIBDR, FC and CRP measurements were obtained from an extract by the local 178 biochemistry team describing tests recorded up to August 13, 2024. For each
- 179 individual, all measurements within seven years from diagnosis were considered. 180 Failed tests, for example due to contamination, were discarded. All FC tests were
- performed from stool samples using the same ELISA technology. 17 Due to limits of 181
- 182 detection, observations <20 μg/g were recoded to 20 μg/g whilst observations >1250
- 183 μg/g were mapped to 1250 μg/g. Such observations were treated as censored when
- 184 applying the inclusion exclusion criteria described above. CRP was measured from
- 185 blood samples; observations for which only an upper bound was available, e.g. <1
- 186 mg/L, were mapped to the corresponding upper bound.
- 188 Test results for the Danish data were obtained from subjects' local biochemistry teams.
- 189 As national biochemistry data were only nationwide from 2015, only measurements
- 190 within five years from the date of diagnosis were considered. Test results between
- 191 January 2015 and September 2022 were considered. For FC, observations >1800µg/g
- 192 were censored, whilst CRP observations <4mg/L were censored. As with the LIBDR,
- 193 censored observations were recoded to their respective threshold.

To smooth out short-term fluctuations CRP measurements were further processed by considering median values within fixed time intervals (Supplementary Note 2).

Longitudinal biomarker clustering

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

The Scottish and Danish data were analysed separately. FC and CRP trajectories (after log-transformation) were modelled separately using latent class mixed models (LCMMs).¹⁸ enabling clustering of subjects that share similar longitudinal trajectories. LCMM consists of two submodels: one which captures longitudinal behaviour, and one which captures cluster assignment. Fixed effects for the longitudinal submodel were specified as natural cubic splines. The intercept was used as a patient-level random effect. The cluster assignment submodel used IBD type as a covariate. Model definitions and hyper-parameter choices are shown in Supplementary Note 3.

As the number of clusters is not known a priori, the optimal model was found using a grid search approach. We considered models with 2-10 clusters for both FC and CRP. ¹⁹ Akaike information criterion (AIC), ¹⁹ Bayesian information criterion (BIC), and visual inspection of cluster trajectories were used to compare models with different specifications and determine the most appropriate number of assumed clusters. The optimal number of clusters was chosen based on the LIBDR dataset as it has a more precise phenotyping (date of diagnosis, IBD type and additional information). The chosen number of clusters was then applied when analysing the Danish cohort.

LCMM calculates, for each individual, the probability of being assigned to each cluster. In subsequent analyses, each individual was assigned to the cluster with the highest probability. The distribution of cluster assignment probabilities was used to assess uncertainty in these allocations with respect to follow-up length. This was defined as the time difference between diagnosis and the last available biomarker measurement (FC or CRP, depending on the analysis). For each cluster, the average probability of individual-specific probabilities of cluster assignment were reported.

To avoid displaying potentially identifiable individual-level data, exemplar trajectories within each cluster were visualised as aggregated trends, with measurements summarised as the median across six randomly selected individuals. For the LIBDR

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

analysis, clusters were ordered based on the area under the overall biomarker trend inferred for each cluster (a proxy for cumulative inflammatory burden). The clusters found in the Danish cohort were ordered manually to resemble similar trajectories. Associations with respect to cluster assignments To facilitate the interpretation of each cluster, we considered potential associations between cluster assignments and patient phenotypes. Violin plots and percentage bar plots were used as a visual summary when considering continuous (age) and discrete (sex, IBD type and, for LIBDR, additional phenotyping) covariates, respectively. Multinomial logistic regression was used to quantify associations between cluster assignments and patient phenotypes (covariates). Multivariate models were considered, and the associated 95% confidence intervals are reported. Individuals with missing covariate values were excluded when fitting each model. As a sensitivity analysis, the analysis was repeated after excluding individuals with a low probability for cluster assignment (<0.5). Prescribing trends To compare patterns of advanced therapy (AT) across clusters, the cumulative distribution of first-line advanced therapy use was calculated for both the Scottish and Danish cohorts. As primary care prescribing data were available for Danish subjects, patterns for systemic corticosteroid and immunomodulator use were also investigated. Results are reported stratified by IBD type (CD and UC only). Comparison between FC and CRP cluster assignments For subjects meeting the criteria for both FC and CRP analyses, the relationship between FC and CRP cluster assignment was visualised using alluvial plots and sideby-side comparisons of mean cluster trajectories for the optimal models. Stratified results for CD and UC subjects are also reported. Software All analysis was performed in the R statistical software²⁰; software/package versions are shown in Supplementary Note 4. Analytical reports for the LIBDR have been

generated using the Quarto scientific publishing system and are hosted online (https://vallejosgroup.github.io/IBD-Inflammatory-Patterns/) with code used to perform the LIBDR and Danish analyses publicly available under an open source license (https://github.com/VallejosGroup/IBD-Inflammatory-Patterns).

Role of the funding source

Funders were not involved in the study design, collection, analysis, or interpretation

of the data, writing, or decision to submit the paper for publication.

Results

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

Cohort derivation and description

In the Scottish cohort, 10545 FC and 49364 (9898 after preprocessing) CRP observations were available. In the Danish cohort, 67986 FC and 207141 (40648 after preprocessing) CRP observations were available. Figure 1 outlines the derivation of the cohorts; Table 1 describes key demographic factors. The distribution of logtransformed FC and CRP values is shown in Figure S4.




Figure 1. Derivation of the study cohorts based on separate faecal calprotectin (FC) and C-reactive protein (CRP) inclusion/exclusion criteria. A 7-year follow-up period was used for LIBDR, a 5-year follow-up period was used for the Danish cohort.

272

273

	The Lothian IBD Registry		Danish national registry			
	FC analysis (n = 1036)	CRP analysis (n = 1838)	Overlap (n = 808)	FC analysis (n = 7880)	CRP analysis (n = 10041)	Overlap (n = 5685)
Age at diagnosis	33 (25–75)	37 (24–55)	32 (20–50)	33 (22–53)	38 (24–57)	32 (22-52)
Male sex	503 (48-6%)	956 (52.0%)	397 (49-1%)	3648 (46-3%)	4693 (46·7%)	2594 (45-6%)
IBD type						
Crohn's disease (CD)	544 (52·5%)	805 (43-8%)	451 (55-8%)	3931 (49-9%)	4415 (44-0%)	2954 (52·0%)
Ulcerative colitis (UC)	380 (36·7%)	847 (46·1%)	276 (34-2%)	3949 (50-1%)	5626 (56-0%)	2731 (48.0%)
IBDU	112 (10-8%)	186 (10·1%)	81 (10-0%)			
Baseline FC (µg/g)	740 (320– 1070)		760 (330– 1081)	574 (148- 1613)		652 (171- 1737)
FC observations	9 (6–13)		9 (6–14)	7 (4–11)		8 (5-12)
Baseline CRP (µg/mL)		8 (3–24)	8 (3–20)		12 (3-45)	20 (3-38)
Total unprocessed CRP observations		20 (10–36)	26 (14–36)		19 (9–32)	22 (12-34)
Total CRP observations after pre- processing		6 (4–7)	6 (5–7)		4 (3–5)	4 (3-5)
Advanced therapies (AT)						
AT within follow-up for CD	270 (49-6%)	374 (46-5%)		2108 (53-6%)	2246 (50-9%)	
AT within one year for CD	129 (23.7%)	167 (20.7%)		1517 (38-6%)	1549 (35·1%)	
AT within follow-up for UC	108 (28-4%)	85 (10-0%)		1293 (32·7%)	1702 (30-3%)	
AT within one year for UC	42 (11·1%)	35 (4-1%)		789 (20-0%)	978 (17-4%)	
Crohn's disease						
Montreal location						
L1	168 (30-9%)	249 (30-9%)	136 (30-2%)			

L2	200 (36-8%)	287 (35-7%)	157 (34-8%)
L3	169 (31-1%)	246 (30-6%)	153 (33-9%)
Missing	7 (1.3%)	23 (2.9%)	5 (1.1%)
Upper GI inflammation			
Present	77 (14-2%)	87 (10-8%)	68 (15-1%)
Not Present	467 (85.8-4%)	718 (89-2%)	383 (84-9%)
Montreal behaviour			
B1	443 (81-4%)	607 (75-4%)	364 (80-7%)
B2	63 (11.5%)	110 (13.7%)	54 (12-0%)
В3	28 (5·1%)	61 (7-6%)	25 (5.5%)
Missing	10 (1.8%)	27 (3-4%)	8 (1.8%)
Perianal disease			
Present	79 (14-5%)	113 (14-0%)	68 (15·1%)
Not Present	459 (84-4%)	673 (83-6%)	379 (84-0%)
Missing	6 (1.1%)	19 (2-4%)	4 (0.9%)
Smoking status			
Current or previously	166 (30-5%)	274 (34·0%)	138 (30-6%)
Never	352 (64-7%)	484 (60-1%)	293 (65-0%)
Missing	26 (4.8%)	47 (5.8%)	20 (4-4%)
Ulcerative colitis			
Montreal extent			
E1	50 (13-2%)	155 (18-3%)	27 (9.8%)
E2	155 (40-8%)	330 (39.0%)	111 (40-2%)
E3	170 (44·7%)	341 (40-3%)	133 (48·1%)

Missing	5 (1.3%)	21 (2.5%)	5 (1.8%)
Smoking status			
Current or previously	121 (31-8%)	336 (39.7%)	89 (32-2%)
Never	237 (62-4%)	444 (52·4%)	167 (60-5%)
Missing	22 (5·8%)	67 (7.9%)	20 (7·2%)

Table 1. Demographic and clinical data at diagnosis for subjects meeting the faecal calprotectin (FC) or C-reactive protein (CRP) study inclusion criteria. Continuous data are presented as median and interguartile range. Categorical data are presented as counts and percentages. Missingness is only directly reported if values were missing. The column labelled as "Overlap" denotes subjects which met the inclusion criteria for both FC and CRP modelling. Missing observations for upper gastrointestinal inflammation were assumed to be "not present" (Supplementary Note 1). Missingness was not inferred to be a value for any other variable. There are no IBDU diagnoses reported for the Danish cohort as these were mapped to either CD or UC (Supplementary Note 1).

Modelling of FC trajectories

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

For the LIBDR cohort, AIC suggested the 10-cluster model (Figure S5), whilst BIC suggested the 9-cluster model (Figure S6) was most appropriate (Table S1, Figure S7 (A)). However, the 8-cluster model was chosen as a parsimonious choice, as it captures the main observed longitudinal patterns without generating very small clusters (<50 individuals) which could be difficult to interpret.

Figure 2 (A) shows representative cluster profiles for the 8-cluster model in the Lothian population, ordered from lowest (FC1) to highest (FC8) cumulative inflammatory burden. FC2 (n=67; ~6%) represents low FC values throughout the whole observation period. Instead. FC1 (n=140: ~14%), FC3 (n=157: ~15%), and FC7 (n=244: ~24%) were characterised by initially high FC values (>250 μg/g) which decreased over time at different rates. Whilst FC1 exhibited a sharp decrease within the first year, the decrease was more gradual for FC3 and FC7, where FC was normalised (<250 µg/g) approximately around two and five years post diagnosis, respectively. Furthermore,

FC4 (n=103; ~10%), FC5 (n=67; ~6%) and FC6 (n=64; ~6%) captured relapsing and remitting patterns of gastrointestinal inflammation. Finally, FC8 (n=194; ~19%) represented individuals with consistently high FC values.

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

The 8-cluster model was then applied to the Danish data. Despite being a completely independent analysis, using data from another healthcare system, and with a shorter follow-up period, the shape of the cluster-specific trajectories largely matched those found for the LIBDR cohort (Figure 2 (B)). In particular, the same rapid remitters (FC1), delayed remitters (FC3 and FC7), and non-remitters (FC8) clusters were observed. The most marked difference is within the relapsing-remitting clusters (FC4-6), which may be partly explained by the smaller size of these clusters in the LIBDR cohort. The proportion of individuals allocated to each cluster differed between cohorts. For example, whilst FC2 represented ~6.5% in the Scottish cohort, nearly one third of patients (~30·1%) were assigned to FC2 in the Danish cohort.

Associations with respect to FC cluster assignments

Associations with respect to age, sex and IBD type were considered in both cohorts with the relapsing-remitting clusters (FC4–6) grouped for ease of comparison. Effect sizes were largely consistent between both cohorts (Figures S8-S10). The effect of age differed across clusters (Figure S8), but this may be partially due to differences in treatment between younger and older individuals. Males were more likely to be assigned to the clusters with the highest inflammatory burden, FC7 and FC8 (Figure S9, S10 and S11). IBD type was associated with cluster assignments (Figure S12). For example, FC1 (rapid remitters) was enriched by patients with CD in both cohorts (62.9% in LIBDR and 63.0% in the Danish data vs 50.9% and 45.6% respectively elsewhere). However, whilst the relapsing-remitting clusters (FC4-6) mostly consists of individuals with UC in the Danish cohort (87.7%), this was not the case for LIBDR.

For the LIBDR cohort, a similar analysis was performed after stratifying by IBD type (UC and CD only) and considering additional phenotyping (Figures \$13–\$19). In most cases, effect sizes were not statistically significant (in some cases this was due to low counts and small cluster sizes). However, amongst patients with CD, those without upper GI inflammation were more likely to be assigned to the clusters with the lowest

inflammatory burden, FC1 or FC2 (2.4% and 3.03% L4 vs 18.1% elsewhere; Figure \$13). Finally, UC patients with ulcerative proctitis were found to be less likely to be assigned to FC3 (2.44% E1 versus 14.2% elsewhere: Figure S19).

FC cluster assignment and IBD therapy usage

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

In Scottish and Danish patients with CD, 23.7% and 38.6% received an advanced therapy (AT) within one year of diagnosis, respectively (Table 1). This increased to 49.6% and 53.6% by the end of the observation period (seven and five years respectively). For patients with UC, 11·1% and 20·0% received an AT within one year of diagnosis, respectively for Scottish and Danish patients. This increased to 28.4% and 32.7% by the end of the observation period. Overall AT rates and the distribution of time to first AT were not homogeneous across clusters (Figure 3). For example, whilst AT prescription rates in FC1 largely matched the overall FC cohort, prescriptions were generally earlier in this cluster, especially in patients with CD. In both FC7 (the very delayed remitting cluster) and in FC8 (the cluster with consistently high inflammation levels), the cumulative AT rates for CD were high. By the end of followup in Scotland and Denmark, 55-1% and 80-9% were on AT in FC7 and 56-8% and 56.7% in FC8. However, early prescriptions of AT were noticeably lower than in other clusters including FC1.

The detailed therapy data available from the Danish registries allows for a more granular exploration of multiple lines of advanced therapy, immunosuppressant use and courses of corticosteroids separately for CD (Figure S34) and UC (Figure S35). In CD, FC1 is characterised by the early introduction of steroids, AT and immunosuppressants, with therapy remaining remarkably stable throughout (no additional lines of AT and no further courses of steroids). FC2 has the highest number of patients not on AT after 1 (72.3%) and 5 years (62.5%). In FC3 (delayed remitters), FC4 and FC6 (the two main relapsing remitting clusters for patients with CD), second, third and fourth line AT prescriptions are noted along with multiple courses of corticosteroids. These observations would be consistent with the challenges of treating patients with IBD, where in some patients it takes time to find the right drug for the right patient to induce deep remission, with multiple steroid courses used along the way. A similar pattern is seen in FC7, where 25.5% had 3 or more different advanced

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

therapies, 23.7% had 5 or more steroid courses and 87.2% received an immunomodulator within the five years. These are the largest numbers across all the clusters, suggesting that multiple attempts are being made with different therapies to control active disease with eventual success. In FC8, 29-3% and 13-1% of patients had tried ≥2 and ≥3 different types of AT respectively, suggesting the persistently elevated inflammation levels during follow-up are at least in part due to non-response to multiple lines of therapy. In patients with UC, FC2 has the highest percentage of patients without treatment, FC1 is relatively stable over time, and FC8 has the highest percentage of multiple types of treatment. Surgical resections for patients with CD are shown in Figure S36. It is noteworthy that some of the patients assigned to a delayed remitting group (FC3 and FC7) were having surgical resections later in follow-up. Colectomy rates in UC were overall very low (Figure S37), but not evenly distributed with higher rates in those clusters with higher cumulative inflammatory burdens (10.5% in FC8 compared to 2.8% and 1.4% in FC1 and FC2).




Figure 2. Cluster trajectories obtained from LCMM assuming eight clusters fitted to FC data (logtransformed) in (A) the Lothian IBD Registry and (B) Danish national registry data. The blue and red lines indicate predicted mean cluster profiles with 95% confidence intervals for the Lothian IBD Registry and Danish data respectively. The yellow dotted lines indicate log(250µg/g). For visualisation purposes, pseudo subject-specific trajectories have been generated by amalgamating observations from randomly selected groups of six subjects. Clusters are ordered from lowest (FC1) to highest (FC8) cumulative inflammatory burden in the Lothian data with Danish cluster labels chosen based on visual similarity to the former clusters. Cluster sizes are shown as panel titles.

Modelling of CRP trajectories

380

381

382

383

384

385

386

387

388

389

390 391

392

393

AIC and BIC both suggested the 8-cluster model was the most appropriate (Table S2) for the LIBDR cohort. Visual inspection supported this finding as the 9-cluster model did not identify new trajectories when compared to the 8-cluster model, producing two trajectories with consistently low CRP (Figure S20). In contrast, the 7-cluster model (Figure S21) lacks one of the clinically interesting trajectories, characterised by an

initially elevated CRP which then decreases to slightly above biochemical remission after one year, when compared to the 8-cluster model.

Figure 4 (A) presents exemplar cluster profiles for the 8-cluster model. Over a third of subjects (n=702: ~38%) were assigned to CRP1, defined by consistently low CRP (< 5µg/mL). CRP2 (n=225; ~12%) was characterised by high CRP at diagnosis which rapidly decreased shortly thereafter remaining low. CRP3 (n=51: ~3%) and CRP4 (n=60; ~3%) are both small clusters with the former described by low CRP until the last year of follow-up and the latter presenting low inflammation within the first year before increasing until the third year where the inflammation then decreases again. CRP5 (n=110; 6%) is characterised by elevated CRP at diagnosis which then decreases gradually over time. CRP6 (n=434; 24%) consists of trajectories which are elevated at diagnosis which then falls slightly for the first two years after diagnosis, remaining elevated across the remaining duration of follow-up. CRP8 (n=172: 9%) is consistently elevated and does not change over time. As in the FC analysis, the shape of CRP clusters inferred for the LIBDR cohort was largely recapitulated when the 8cluster model was applied to the Danish cohort (Figure 4 (B)).

Associations with CRP cluster assignments

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

Figures S22-S24 visualise the distribution of age, sex and IBD type within each CRP cluster. Results were largely consistent across the cohorts. Older patients were more likely to be assigned to a CRP cluster with higher cumulative inflammatory burden (Figure S22). IBD type was not evenly distributed among clusters (Figure S24), with CRP1, CRP3, CRP4 and CRP7 enriched for UC patients (59.3%, 56.8%, 61.7% and 72.6% vs 32.3% elsewhere in LIBDR, with similar proportions for the Danish data. The association plots for CD and UC disease sub-phenotypes and CRP cluster assignment are shown in Figures <u>\$25</u>–<u>\$30</u>.

AT prescribing patterns in CRP clusters are shown in Figure S31.




Figure 3. FC cluster-specific cumulative distribution for first-line advanced therapy prescribing for Crohn's disease (red) and ulcerative colitis (teal) subjects in (A) the Lothian IBD Registry and (B) national Danish registry data. Clusters are ordered from lowest (FC1) to highest (FC8) cumulative inflammatory burden. The number of CD and UC subjects present in each cluster is displayed as panel titles. Total advance therapy prescribing (as a percentage of the corresponding group) within seven/five years from diagnosis is shown next to each distribution curve. Curves which would describe fewer than ten subjects are not shown.

423

424

425

426

427

428




Figure 4. Cluster trajectories obtained from LCMM assuming eight clusters fitted to processed CRP data (log-transformed) for subjects in (A) the Lothian IBD Registry and (B) national Danish registry data. Blue and red lines indicate predicted mean cluster profiles with 95% confidence intervals. The yellow dotted lines indicate log(5µg/mL). For visualisation purposes, pseudo subject-specific trajectories have been generated by amalgamating observations from randomly selected groups of six subjects. Clusters are ordered from lowest (CRP1) to highest (CRP8) cumulative inflammatory burden. Cluster sizes are shown as panel titles.

432

433

434

435

436

It is made available under a




Figure 5. Exploration of cluster assignment uncertainty for A) faecal calprotectin (FC) and B) CRP clusters in the Lothian IBD Registry cohort. LCMM assigns individuals to the cluster with the highest estimated probability. For individuals assigned to a given cluster, bars show the average probability of cluster assignment to each possible cluster. Results are stratified according to follow-up length,

438 439

440

441

defined as the time difference between diagnosis and the last available biomarker measurement (FC or CRP for A) and B), respectively). Clusters are ordered from lowest (FC1 and CRP1) to highest (FC8 and CRP8) cumulative inflammatory burden, with adjacent clusters coloured sequentially in the plots for FC (black to yellow) and CRP (blue to yellow).

Uncertainty in cluster assignments

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

The relationship between the uncertainty in cluster assignments and follow-up length was explored for the LIBDR cohort. In the FC analysis, with the exception of FC2, cluster assignments were on average more uncertain for those with a short follow-up (Figure 5 (A)). This is particularly the case for FC clusters that share similar earlier trends. For example, individuals assigned to FC1 (rapid remitters) had a low average probability of being assigned to FC8 (non-remitters) and vice-versa, even for those with a short follow-up. This is not the case for FC3 and FC6, both of which capture similar FC trajectories within the first two years. Indeed, those assigned to FC6 with less than two years of follow-up also have, on average, a high probability of being assigned to FC3. On average, cluster assignments were less uncertain in the CRP analysis, even for individuals with a short follow-up (Figure 5 (B)). This is expected as CRP clusters are associated with more distinct early trajectories.

Comparison of FC and CRP clustering

In the LIBDR cohort, all FC clusters were well represented amongst the 808 subjects included in both analyses (overlap sub-cohort), but the proportion in CRP8 was low (~27% of CRP8 was in the overlap sub-cohort vs ~46% elsewhere; Figure S32). As shown in Figure 6 (A), there was low agreement between FC and CRP clustering in the overlap sub-cohort (the same occurred in the Danish data, Figure \$33). Whilst most subjects in FC1 (71.6%) were also in CRP1 or CRP2, this relationship was not mirrored as 81.2% of subjects in the latter two CRP clusters were assigned to substantially different FC clusters. However, CRP8 did overlap with elevated FC as the majority of subjects in this cluster (80.8%) were assigned to either FC7 or FC8.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.




Figure 6. Comparison between faecal calprotectin (FC) and processed CRP for models with chosen specification (three NCS) assuming eight clusters for subjects in the Lothian IBD Registry cohort.

Results are reported based on the overlap cohort, consisting of 808 subjects included in both the FC and CRP analysis. (A) all subjects; (B) Crohn's disease; and (C) ulcerative colitis. Each segment denotes the size of the cluster whilst the alluvial segments connecting the nodes visualises the number of subjects shared between clusters.

Discussion

We have characterised IBD behaviour using long-term longitudinal trends of objective inflammatory markers routinely collected for clinical care. Our analysis has uncovered eight clusters with distinct inflammatory profiles based on FC and CRP, respectively. This was replicated in two independent cohorts, one based in Scotland (Lothian) and

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

one in Denmark (nationwide). Our data highlights the heterogeneity of the disease course, and presents a novel approach for understanding real-world inflammatory activity patterns in IBD patients. For the first time, we are capturing the dynamic nature of the disease in a more biologically nuanced way than traditional behaviour endpoints such as treatment escalation, surgery and "Montreal progression". This represents a marked shift from the traditional symptom-based behaviour profiles exemplified by the IBSEN cohorts over a decade ago. 10,11

This study builds on our earlier proof-of-concept work, where we first demonstrated the feasibility of using long-term individualised profiles of FC to cluster IBD patients with CD.¹⁷ In our previous analysis of Lothian patients, we identified four distinct FC clusters: one cluster with persistently high FC (non-remitters) and three clusters with different downward longitudinal trends. Here, we expand upon this by considering a substantially larger Lothian IBD cohort (FC cohort, n=1036; CRP cohort, n=1838), with longer follow-up, not excluding patients based on indicators of disease severity, and also including patients with UC or IBDU. In addition, we modelled CRP. This has generated results with greater representativeness across IBD phenotypes, uncovering more granular structure with eight distinct FC clusters rather than four. Whilst the modelling suggested further partitioning of the FC data was possible (Figure S5, Figure S7 (A)), we selected the eight-cluster model as a parsimonious choice that captured the key inflammatory patterns (Figure 2). Notably, the CRP data also partitioned into eight distinct clusters. Together, the clusters broadly fall into four patterns of inflammatory behaviour mirroring those recognised by gastroenterologists managing IBD patients (i) rapid remitters (FC1 and CRP2), (ii) delayed remitters (FC3, FC7 and CRP5), (iii) relapsing-remitters (FC4-6 and CRP4 and CRP7), and (iv) nonremitters (FC8 and CRP6 and CRP8). These classifications provide new insights into the inflammatory course of IBD patients.

Critically, replication in two independent IBD cohorts demonstrates the robustness of our findings, indicating that the longitudinal patterns described above characterise inherent properties of the disease course. Both cohorts represent real-world IBD populations with complementary properties. The Danish cohort is larger (n = 7880 and n = 10041 for FC and CRP, respectively), has nation-wide coverage, and more detailed treatment information (including primary care prescribing), but phenotyping is

more limited (e.g. no Montreal classification). Instead, LIBDR represents a single Scottish health board and is more moderate in size (n = 1036 and n = 1838 for FC and CRP, respectively), but has a longer longitudinal follow-up. Moreover, extensive data curation provides more accurate diagnostic data and additional phenotyping, helping to understand how the clusters relate to well-established IBD classifications.

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

We observed broadly poor agreement between FC and CRP clusters, although there was overlap amongst those at the varying ends of the inflammatory spectrum with FC1 and FC2 correlating with CRP1 and CRP2 (rapid remitters with low cumulative inflammatory burden), and FC7 and FC8 correlating with CRP6-8 (non-remitters with high cumulative inflammatory burdens). Broadly though, the lack of overlap between the two is not surprising. CRP is a marker of systemic inflammation, whilst FC is more specific for detecting inflammation at a mucosal level. Hence, why both biomarkers are complimentary when monitoring patients with IBD. Studies have also shown that a proportion of IBD patients will have lower CRP values at diagnosis, 22 as is seen in CRP1 which is significantly enriched for UC cases.

We observed several important observations regarding cluster assignment. All IBD subtypes featured in each cluster, but cluster assignment was unevenly distributed across IBD types (Figures S12 and S24). In CD, although patients with L4 disease were less represented in FC1 and FC2, there was no association with ileal versus colonic disease location. Males were slightly overrepresented in the FC8 cluster, which is characterised by persistently elevated values. Interestingly, in the recent SEXEII study, they observed male patients with UC were more likely to have extensive colonic involvement and abdominal surgery, which may account for this finding.²³ CRP cluster membership was also associated with smoking and older age, with both more likely to have higher inflammatory burdens.

Multiple lines of evidence, including the recent PROFILE study,²⁴ have clearly demonstrated improved disease control and outcomes in Crohn's patients receiving early AT. As such, we anticipated that the biggest driver of inflammatory patterns over time would be AT and that this effect would be more pronounced in CD versus UC especially given the era of our cohort. Indeed, rates of AT use were not homogenous across clusters or IBD subtypes. Overall, in the FC LIBDR cohort, AT were used in

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

49.6% of CD patients of which 47.7% started AT in the first year. In FC1, similar rates of AT were used for CD patients, however they were used earlier, suggesting their positive benefit in rapidly inducing and maintaining remission. Rates of AT prescriptions for patients with CD in FC8 (persistently high levels of inflammatory behaviour) were similar, but started later in the disease course, which may have negatively affected the ability to bring about remission of disease. This cluster may also represent a more refractory group of patients, with a higher risk phenotype. Whilst this may provide additional support for the use of early AT, a causal interpretation of these effects is not possible in this study, which is based on observational data. Additional work with alternative cohorts where treatment assignment is randomised is planned.

Our study also highlights the importance of using a probabilistic approach to account for uncertainty in cluster assignments. Indeed, we observed higher uncertainty for subjects with a shorter longitudinal follow-up, particularly for FC clusters (Figure 5). In such cases, we cannot confidently assign individuals to a specific cluster. Instead, cluster assignment probabilities are sometimes evenly split across multiple clusters. mostly between those with similar earlier behaviour and inflammatory burdens. This effect is less prominent in CRP cluster assignments, partly due to the more distinct early trajectories across CRP clusters. As such, we anticipate that a multivariate approach which simultaneously considers other biomarkers of disease activity, such as haemoglobin, albumin, and platelet count, may further increase the robustness of cluster assignments. Such analysis may also consider pre-diagnostic biomarker measurements, following the recent observations in Danish registry data, 25 as well as metabolomics, genetics or microbiome data to inform cluster assignments.

Critically, this study is limited by the use of observational data. Beyond AT use, the frequency and amount of biomarker measurements is likely to be higher for those with a more severe disease, and very mild cases may be excluded from our cohort. Moreover, FC and CRP clusters cannot be directly used in a prognostic way. Indeed, future work is needed to assess associations between clusters and IBD related complications (such as steroid use, hospitalisations and surgery) but also nonconventional complications related to a high cumulative inflammatory burden, such as major cardiovascular adverse events, neuropsychiatric illness, and malignancy. Such

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

analyses will ultimately support the development of a low cost clinical support tool to help deliver precision medicine to patients with IBD. Classifying patients by their inflammatory behaviour may better inform therapy decisions, including timing of AT, as well as monitoring and follow-up requirements. This is a paradigm shift in thinking about disease behaviour compared with the previous symptom based profiles first reported by the IBSEN cohorts. Moreover, this approach - rooted in data that is widely available in clinical settings²⁶ and probabilistic modelling- paves the way for predictive analytics integrated into a clinical support tool for population wide risk stratification and individual patient level prognostication and treatment. Data sharing statement As the data collected for this study has been derived from unconsented patient data, it is not possible to share subject-level data with external entities. Detailed summary level data is available online at https://vallejosgroup.github.io/IBD-Inflammatory-Patterns. The code used to conduct the analysis is also publicly available (https://github.com/VallejosGroup/IBD-Inflammatory-Patterns). Analyses performed on the DK cohort is based on data from the Danish National Health registries (https://sundhedsdatastyrelsen.dk). It is protected by the Danish Act on Processing of Personal Data and access requires application to the Danish Data Protection Agency and the Danish Health Data Authority. In addition, data handling must be carried out by a Danish institution. Author contributions CAV, CWL, and NCC were involved in conceptualising the study. CRB, SO, ATE, GRJ, and NP curated the LIBDR data. NCC and CAV implemented computer code, tested existing code components, and conducted the formal analysis and visualisation for the LIBDR. TJ obtained funding for and built the Danish PREDICT data infrastructure on which the Danish analyses were performed. MVV curated the Danish data and conducted the validation analyses and visualization on the Danish data. The original draft was written by NCC, NP, ATE, CMR, MVV, CWL and CAV with all authors

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

involved in reviewing and editing the manuscript. KMG, CWL, CAV, AS and TJ provided supervisory support. Competing interests NP has served as a speaker for Janssen, Takeda and Pfizer. BG has acted as consultant to Galapagos and Abbvie and as speaker for Abbvie, Jansen, Takeda, Pfizer and Galapagos. GRJ has served as a speaker for Takeda, Janssen, Abbvie, Fresnius and Ferring. TJ has served as a speaker and/or consultant for Ferring and Pfizer. CWL has acted as a speaker and/or consultant to AbbVie, Janssen, Takeda, Pfizer, Galapagos, GSK, Gilead, Vifor Pharma, Ferring, Dr Falk, BMS, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Sandoz, Celltrion, Cellgene, Amgen, Samsung Bioepis, Fresenius Kabi, Tillotts, Kuma Health, Trellus Health and Iterative Health. None of the other authors report any conflicts of interest. **Funding** CWL is funded by a UKRI (UK Research and Innovation) Future Leaders Fellowship 'Predicting outcomes in IBD' (MR/S034919/1). G-RJ is funded by a Wellcome Trust Clinical Research Career Development Fellowship. NC-C was partially supported by the Medical Research Council and The University of Edinburgh via a Precision Medicine PhD studentship (MR/N013166/1). MVV, AS, and TJ are funded by a Center of Excellence Grant (DNRF148) to TJ from the Danish National Research Foundation. Acknowledgements This work uses data provided by patients and collected by the NHS as part of their care and support. The Lothian component of this work has made use of the resources provided by the Edinburgh Compute and Data Facility (ECDF). The analysis of the Danish cohort was performed using the National Genome Center platform. References

1. Jones GR, Lyons M, Plevris N, et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut. 2019;68(11):1953-1960.

643 doi:10.1136/gutjnl-2019-318936

661

664

665

666

667

668

669

670

675

676

677

678

679

680

681

682

683

684

- 644 2. Hamilton B, Green H, Heerasing N, et al. Incidence and prevalence of 645 inflammatory bowel disease in Devon. UK. Frontline Gastroenterol. 646 2021:12(6):461-470. doi:10.1136/flgastro-2019-101369
- 647 3. Cushing K, Higgins PDR. Management of Crohn disease: A review. JAMA. 648 2021;325(1):69. doi:10.1001/jama.2020.18936
- 649 4. Gros B. Kaplan GG. Ulcerative colitis in adults: A review, JAMA. 650 2023;330(10):951. doi:10.1001/jama.2023.15389
- 651 5. Zhou RW, Harpaz N, Itzkowitz SH, Parsons RE. Molecular mechanisms in colitis-652 associated colorectal cancer. Oncogenesis. 2023;12(1):48. doi:10.1038/s41389-653 023-00492-0
- 654 6. Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association 655 between level of fecal calprotectin and progression of Crohn's disease. Clin 656 Gastroenterol Hepatol. 2019;17(11):2269-2276.e4. doi:10.1016/j.cgh.2019.02.017
- 657 7. Plevris N, Fulforth J, Lyons M, et al. Normalization of fecal calprotectin within 12 658 months of diagnosis is associated with reduced risk of disease progression in 659 patients with Crohn's disease. Clin Gastroenterol Hepatol. 2021;19(9):1835-660 1844.e6. doi:10.1016/j.cgh.2020.08.022
- 8. Verstockt B. Noor NM. Marigorta UM. et al. Results of the Seventh Scientific 662 Workshop of ECCO: Precision medicine in IBD—Disease outcome and response 663 to therapy. J Crohns Colitis. 2021;15(9):1431-1442. doi:10.1093/ecco-jcc/jjab050
 - 9. Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17-30. doi:10.1016/S2468-1253(19)30333-4
 - Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430-1438. doi:10.1016/j.cgh.2007.09.002
- 671 Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years 672 of ulcerative colitis: Results from a population-based inception cohort (IBSEN) Study). Scand J Gastroenterol. 2009;44(4):431-440. 673 674 doi:10.1080/00365520802600961
 - Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-12. reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014;63(1):88-95. doi:10.1136/gutjnl-2013-304984
 - 13. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol Hepatol. 2005;19:5A-36A. doi:10.1155/2005/269076
 - Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol, 1989:24(sup170):2-6, doi:10.3109/00365528909091339
 - Sorlie P, Wei GS. Population-based cohort studies: Still relevant? J Am Coll 15. Cardiol. 2011;58(19):2010-2013. doi:10.1016/j.jacc.2011.08.020
- Agrawal M, Christensen HS, Bøgsted M, Colombel JF, Jess T, Allin KH. The 686 16. 687 rising burden of inflammatory bowel disease in Denmark over two decades: A 688 nationwide cohort study. Gastroenterology. 2022;163(6):1547-1554.e5. 689 doi:10.1053/j.gastro.2022.07.062
- 690 17. Constantine-Cooke N, Monterrubio-Gómez K, Plevris N, et al. Longitudinal 691 fecal calprotectin profiles characterize disease course heterogeneity in Crohn's 692 disease. Clin Gastroenterol Hepatol. 2023;21(11):2918-2927.e6.

- 693 doi:10.1016/j.cgh.2023.03.026
- 694 18. Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models 695 using latent classes and latent processes: The R package lcmm. *J Stat Softw.* 696 2017;78(2):1-56. doi:10.18637/jss.v078.i02
- 697 19. Stoica P, Selen Y. Model-order selection: A review of information criterion rules. *IEEE Signal Process Mag.* 2004;21(4):36-47. doi:10.1109/MSP.2004.1311138
- 700 20. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing; 2022. https://www.R-project.org/
- 702 21. Clough J, Colwill M, Poullis A, Pollok R, Patel K, Honap S. Biomarkers in 703 inflammatory bowel disease: A practical guide. *Ther Adv Gastroenterol*. 704 2024;17:17562848241251600. doi:10.1177/17562848241251600
- 705 22. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: A predictive factor 706 and marker of inflammation in inflammatory bowel disease. Results from a 707 prospective population-based study. *Gut.* 2008;57(11):1518-1523. 708 doi:10.1136/gut.2007.146357
- 709 23. Gargallo-Puyuelo CJ, Ricart E, Iglesias E, et al. Sex-related differences in the
 710 phenotype and course of inflammatory bowel disease: SEXEII study of ENEIDA.
 711 Clin Gastroenterol Hepatol. 2024;22(11):2280-2290.
 712 doi:10.1016/i.cqh.2024.05.013
- 713 24. Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-714 down versus accelerated step-up treatment strategies for patients with newly 715 diagnosed Crohn's disease (PROFILE): A multicentre, open-label randomised 716 controlled trial. *Lancet Gastroenterol Hepatol*. 2024;9(5):415-427. 717 doi:10.1016/S2468-1253(24)00034-7
- 718 25. Vestergaard MV, Allin KH, Poulsen GJ, Lee JC, Jess T. Characterizing the 719 pre-clinical phase of inflammatory bowel disease. *Cell Rep Med*. 720 2023;4(11):101263. doi:10.1016/j.xcrm.2023.101263
- 721 26. Markowetz F. All models are wrong and yours are useless: Making clinical prediction models impactful for patients. *Npj Precis Oncol.* 2024;8(1):54. doi:10.1038/s41698-024-00553-6

524 Supplemental display items

725 Table of contents

- 726 Supplemental figures
 - Figure S1. Distribution of observation times for diagnostic FC
- Figure S2. Distribution of observation times for diagnostic CRP
- Figure S3. Illustration of how biomarker (faecal calprotectin or CRP)
- observation times were adjusted based on time of diagnostic biomarker
- 731 observation

732 Figure S4. Distribution of diagnostic biomarker measurements across the 733 LIBDR study cohort 734 Figure S5. Cluster trajectories obtained from LCMM assuming ten clusters 735 fitted to FC LIBDR data 736 Figure S6. Cluster trajectories obtained from LCMM assuming nine clusters 737 fitted to FC LIBDR data 738 Figure S7. Alluvial plot visualising cluster assignment for the LIBDR cohort as 739 the number of assumed clusters increases 740 Associations with FC cluster membership 741 Figure S8. Age 742 Figure S9 Sex 743 Figure S10. IBD type 744 Figure S11. Smoking for CD subjects 745 Figure \$12. Montreal location for CD subjects \bigcirc 746 Figure S13. L4 for CD subjects 747 Figure S14. Montreal behaviour for CD subjects 748 Figure S15. Perianal disease for CD subjects 0 749 Figure S16. Smoking for UC subjects Figure S17. Montreal extent for UC subjects 750 751 Figure S18. Sex for UC subjects 752 Figure S19. Sex for CD subjects 753 Figure S20. Cluster trajectories obtained from model assuming nine clusters 754 fitted to CRP LIBDR data 755 Figure S21. Cluster trajectories obtained from model assuming seven clusters 756 fitted to CRP LIBDR data 757 Associations with CRP cluster membership 758 Figure S22. Age Figure S23. Sex 759 760 Figure S24. IBD type 761 Figure S25. Smoking for CD subjects 0 762 Figure S26. Montreal location for CD subjects 763 Figure S27. L4 for CD subjects 764 Figure S28. Montreal behaviour for CD subjects \circ 765 Figure S29. Smoking for UC subjects

Figure S30. Montreal extent for UC subjects

- Figure S31. Time to first-line advanced therapy by CRP cluster assignment
- Figure S32. Proportion of individuals included in the overlap cohort by FC and CRP cluster assignment
 - Figure S33. Comparison between FC and CRP cluster assignment in the Danish cohort.

Supplemental tables 772

766

767

768

769

770

771

773

776

777

778

779

780

- Table S1. Model statistics for models fitted to FC data
- 774 Table S2. Model statistics for models fitted to CRP data

Supplemental figures 775




Figure S1. Distribution of observation times for diagnostic faecal calprotectin (FC) relative to reported date of diagnosis for (A) the Lothian IBD registry cohort and (B) the Danish national registry cohort. Stratified by FC cluster assignment. Diagnostic FC was defined as the first FC test within ±90 days of diagnosis.




Figure S2. Distribution of observation times for diagnostic C-reactive protein (CRP) relative to reported date of diagnosis for (A) the Lothian IBD registry cohort and (B) the Danish national registry cohort. Stratified by CRP cluster assignment. Diagnostic CRP was defined as the first CRP test within ±90 days of diagnosis.

Scenario 1:

782


783

784

785

786

First biomarker measurement within 90 days of reported date of diagnosis is before diagnosis



Biomarker observations are re-timed by the same amount so the first observation now corresponds to diagnosis

Scenario 2:

First biomarker measurement within 90 days of reported date of diagnosis is after diagnosis



Biomarker observations are not re-timed

Figure S3. Illustration of how biomarker (faecal calprotectin or CRP) observation times were adjusted depending on if the diagnostic observation was before or after the date of diagnosis recorded in electronic health records.

787

788

789

790 791

792




Figure S4. Distribution of diagnostic biomarker measurements across the LIBDR study cohort. (A) faecal calprotectin after applying a logarithmic transformation; (B) pre-processed (grouped into time intervals with the median used for multiple measurements) CRP after logarithmic transformation.




Figure S5. Cluster trajectories obtained from LCMM assuming ten clusters fitted to faecal calprotectin data in the Lothian IBD Registry. Red lines indicate predicted mean cluster profiles with 95% confidence intervals. Dotted horizontal lines indicate log(250µg/g). For visualisation purposes, pseudo subject-specific trajectories have been generated by amalgamating observations from groups of six subjects.

796

797

798




Figure S6. Cluster trajectories obtained from LCMM assuming nine clusters fitted to faecal calprotectin data in the Lothian IBD Registry. Red lines indicate predicted mean cluster profiles with 95% confidence intervals. Dotted horizontal lines indicate log(250µg/g). For visualisation purposes,

801

802

pseudo subject-specific trajectories have been generated by amalgamating observations from groups of six subjects.

804

805

806 807

808




Figure S7. Alluvial plot demonstrating how cluster assignment changes for the Lothian IBD registry cohort as the number of assumed clusters increases for the chosen models for (A) faecal calprotectin and (B) C-reactive protein. The clusters found by the 8-cluster models are labelled.




Figure S8. For each FC cluster, violin plots show the distribution of age at diagnosis across subjects, highlighting median and interguartile ranges for (A) the Lothian IBD Registry and (B) Danish national registry data. (C) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for age in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case FC1). The multivariate model includes age, sex and IBD type as covariates. The dashed vertical lines are used as a reference to indicate no effect.

812

813

814

815

816

817




Figure S9. For each FC cluster, barplots show the proportion of individuals with female and male sex. The dashed horizontal line represents overall proportions for (A) the Lothian IBD Registry and (B) Danish national registry data. (C) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for male sex versus females (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. In (C), effect sizes are with respect to the reference cluster (in this case FC1). The multivariate model includes age, sex and IBD type as covariates. The dashed vertical line is used as a reference to indicate no effect.

821

822

823

824

825

826

827




Figure S10. Crohn's disease subjects only. For each FC cluster, barplots show the proportion of individuals with female and male sex. The dashed horizontal line represents overall proportions for (A) the Lothian IBD Registry and (B) Danish national registry data. (C) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for male sex versus females (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort, In (C), effect sizes are with respect to the reference cluster (in this case FC1). The multivariate model includes age, sex and IBD type as covariates. The dashed vertical lines are used as a reference to indicate no effect.

830

831

832

833

834

835

836

837

838




Figure S11. Ulcerative colitis subjects only. For each FC cluster, barplots show the proportion of individuals with female and male sex. The dashed horizontal line represents overall proportions for (A) the Lothian IBD Registry and (B) Danish national registry data. (C) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for male sex versus females (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. In (C), effect sizes are with respect to the reference cluster (in this case FC1). The multivariate model includes age, sex and IBD type as covariates. The dashed vertical lines are used as a reference to indicate no effect.

842

843

844

845

846

847

848




Figure S12. (A) For each FC cluster, panels show the proportion of individuals with Crohn's disease, ulcerative colitis and IBDU respectively in the Lothian IBD Registry. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for IBD type in the Lothian IBD Registry: ulcerative colitis and IBDU versus Crohn's disease (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. (C) For each FC cluster, panels show the proportion of individuals with Crohn's disease and ulcerative colitis respectively in the Danish cohort. (D) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for IBD type in the Danish cohort: ulcerative colitis versus Crohn's disease (baseline

852

853

854

855

856

857

860

861

862

863

864

865

866

867 868 869

870

871

872

873

category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. In the Danish cohort, subjects were not assigned a subtype of "IBDU". Instead, they were assigned either Crohn's disease or ulcerative colitis. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. In (A) and (C), the dashed horizontal line represents overall proportions across the FC cohorts. In (B) and (D), effect sizes are with respect to the reference cluster (in this case FC1). In both cases, the multivariate model includes age, sex and IBD type as covariates. The dashed vertical lines are used as a reference to indicate no effect.




Figure S13. Crohn's disease patients in the Lothian IBD Registry only. (A) For each FC cluster, panels show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and "yes" (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for smoking: yes versus no (baseline category) in a multinomial

875

876

877

878

879

880 881

882

883

884

885

886

887

888

889

890

891

logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort, Effect sizes are with respect to the reference cluster (in this case FC1). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.




Figure S14. Crohn's disease patients in the Lothian IBD Registry only. (A) For each FC cluster, panels show the proportion of individuals with Montreal Location recorded as L1, L2 and L3 respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal Location: L2 and L3 versus L1 (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.




Figure S15. Crohn's disease patients in the Lothian IBD Registry only. (A) For each FC cluster, panels show the proportion of individuals with Montreal L4 (upper gastrointestinal inflammation), recorded as present or non present. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for L4: present versus not present (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case FC1). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

894

895

896

897

898

899

900

901

902




Figure S16. Crohn's disease patients in the Lothian IBD Registry only. (A) For each FC cluster, panels show the proportion of individuals with Montreal behaviour recorded as B1 or B2/B3 respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal behaviour: B2/B3 versus B1 (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

906

907

908

909

910

911

912

913

914




Figure S17. Crohn's disease patients in the Lothian IBD Registry only. (A) For each FC cluster, panels show the proportion of individuals with perianal disease recorded as present or not present. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for perianal disease: present versus not present (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case FC1). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

918

919

920

921

922

923

924

925

926




Figure S18. Ulcerative colitis patients in the Lothian IBD Registry only. (A) For each FC cluster, panels show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and "yes" (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for smoking: yes versus no (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case FC1). The multivariate model includes age, sex, smoking and Montreal extent (E1, E2, E3). The dashed vertical lines are used as a reference to indicate no effect.

931

932

933

934

935

936

937

938




Figure S19. Ulcerative colitis patients in the Lothian IBD Registry only. (A) For each cluster, panels show the proportion of individuals with Montreal extent recorded as E1, E2 and E3 respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal extent: E2 and E3 versus E1 (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case FC1). The multivariate model includes age, sex, smoking and Montreal extent (E1, E2, E3). The dashed vertical lines are used as a reference to indicate no effect.

942

943

944

945

946

947

948




Figure S20. Cluster trajectories obtained from LCMM assuming nine clusters fitted to C-reactive protein data in the Lothian IBD Registry. Red lines indicate predicted mean cluster profiles with 95% confidence intervals. Dotted horizontal lines indicate log(5µg/mL). For visualisation purposes, pseudo subject-specific trajectories have been generated by amalgamating observations from groups of six subjects.

952

953

954




Figure S21. Cluster trajectories obtained from LCMM assuming seven clusters fitted to C-reactive protein data in the Lothian IBD Registry. Red lines indicate predicted mean cluster profiles with 95% confidence intervals. Dotted horizontal lines indicate log(5µg/mL). For visualisation purposes, pseudo subject-specific trajectories have been generated by amalgamating observations from groups of six subjects.

957

958

959

960




Figure S22. For each CRP cluster, violin plots show the distribution of age at diagnosis across subjects, highlighting median and interquartile ranges for (A) the Lothian IBD Registry and (B) Danish national registry data. (C) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for age in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1). The multivariate model includes age, sex and IBD type

964

965

966

967

968

as covariates. The dashed vertical lines are used as a reference to indicate no effect.

970

971 972

973

974

975

976

977

978

979




Figure S23. For each CRP cluster, barplots show the proportion of individuals with female and male sex. The dashed horizontal line represents overall proportions for (A) the Lothian IBD Registry and (B) Danish national registry data. (C) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for male sex versus females (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. In (C), effect sizes are with respect to the reference cluster (in this case CRP1). The multivariate model includes age, sex and IBD type as covariates. The dashed vertical line is used as a reference to indicate no effect.




Figure S24. (A) For each CRP cluster, panels show the proportion of individuals with Crohn's disease, ulcerative colitis and IBDU respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for IBD type: ulcerative colitis and IBDU versus Crohn's disease (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. (C) For each FC cluster, panels show the proportion of individuals with Crohn's disease and ulcerative colitis respectively in the Danish cohort. (D) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for IBD type in the Danish cohort: ulcerative colitis versus Crohn's disease (baseline category) in a multinomial logistic regression model that uses FC cluster

983

984

985

986

987

988

989

992

993

994

995

996

997 998

999

1000

1001

1002

1003

1004

1005

assignment as outcome. In the Danish cohort, subjects were not assigned a subtype of "IBDU". Instead, they were assigned either Crohn's disease or ulcerative colitis. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1). In both cases, the multivariate model includes age, sex and IBD type as covariates. The dashed vertical lines are used as a reference to indicate no effect.




Figure S25. Crohn's disease patients in the Lothian IBD Registry only. (A) For each CRP cluster, panels show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and yes" (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents" overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for smoking: yes versus no (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1).

The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

1006

1007

1008

1009 1010

1011

1012

1013

1014

1015

1016

1017

1018

1019




Figure S26. Crohn's disease patients in the Lothian IBD Registry only. (A) For each CRP cluster, panels show the proportion of individuals with Montreal Location recorded as L1, L2 and L3 respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal Location: L2 and L3 versus L1 (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.




Figure S27. Crohn's disease patients in the Lothian IBD Registry only. (A) For each CRP cluster, panels show the proportion of individuals with Montreal L4 (upper gastrointestinal inflammation), recorded as present or non present. The dashed horizontal line represents overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for L4: present versus not present (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

1023

1024

1025

1026

1027

1028

1029

1030

1031




Figure S28. Crohn's disease patients in the Lothian IBD Registry only. (A) For each CRP cluster, panels show the proportion of individuals with Montreal behaviour recorded as B1 or B2/B3 respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal behaviour: B2/B3 versus B1 (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044




Figure S29. Ulcerative colitis patients in the Lothian IBD Registry only. (A) For each CRP cluster, panels show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and "yes" (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for smoking: yes versus no (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1). The multivariate model includes age, sex, smoking and Montreal extent (E1, E2, E3). The dashed vertical lines are used as a reference to indicate no effect.

1048

1049

1050

1051

1052

1053

1054

1055




Figure S30. Ulcerative colitis patients in the Lothian IBD Registry only only. (A) For each cluster, panels show the proportion of individuals with Montreal extent recorded as E1, E2 and E3 respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal extent: E2 and E3 versus E1 (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1). The multivariate model includes age, sex, smoking and Montreal extent (E1, E2, E3). The dashed vertical lines are used as a reference to indicate no effect.

1059

1060

1061

1062

1063

1064

1065

1066

1067




Figure S31. CRP cluster-specific cumulative distribution for first-line advanced therapy prescribing for Crohn's disease (red) and ulcerative colitis (teal) subjects in (A) the Lothian IBD Registry and (B) national Danish registry data. Clusters are ordered from lowest (CRP1) to highest (CRP8) cumulative inflammatory burden. The number of CD and UC subjects present in each cluster is displayed as panel titles. Curves which would describe fewer than five subjects are not shown.

1070

1071

1072

1073




Figure S32. (A) For each FC cluster in the Lothian IBD Registry, panels show the proportion of individuals included in the overlap LIBDR cohort, which consists of LIBDR subjects included in both the FC and CRP analysis. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) As in (A), but focusing on CRP clusters instead. The dashed horizontal line represents overall proportions across the entire CRP cohort.

1077

1078

1079

1080




Figure S33. Comparison between faecal calprotectin (FC) and processed CRP cluster assignment for the Danish cohort. Results are reported based on the overlap cohort, consisting of 5685 subjects included in both the FC and CRP analysis. (A) all subjects; (B) Crohn's disease; and (C) ulcerative colitis. Each segment denotes the size of the cluster whilst the alluvial segments connecting the nodes visualises the number of subjects shared between clusters.




Figure S34. Prescribing trends over time for Crohn's disease subjects in the Danish faecal calprotectin cohort for (A) commencement of an advanced therapy, (B) commencement of an immunomodulator, and (C) a course of corticosteroids (defined as 1500mg total). Subjects are stratified by FC cluster assignment. For confidentiality reasons, categories with <5 individuals at each time interval were merged with the category with one fewer treatment.

1094

1095

1096

1097




Figure S35. Prescribing trends over time for ulcerative colitis subjects in the Danish faecal calprotectin cohort for (A) commencement of an advanced therapy, (B) commencement of an immunomodulator, and (C) a course of corticosteroids (defined as 1500mg total). Subjects are stratified by FC cluster assignment. For confidentiality reasons, categories with <5 individuals at each time interval were merged with the category with one fewer treatment.

1101

1102

1103




Figure S36. Number of surgical bowel resections over time for Crohn's disease subjects in the Danish cohort. Stratified by faecal calprotectin cluster assignment.




Figure S37. Number of surgical bowel resections over time for ulcerative colitis subjects in the Danish cohort. Stratified by faecal calprotectin cluster assignment.

Supplemental tables 1111

1112

1113

1114

1115

Clusters	Maximum log- likelihood	AIC	BIC
2	-16532-10	33094-20	33168-35
3	-16354-39	32754.78	32868-47
4	-16260-21	32582-42	32735-66
5	-16201-86	32481.71	32674-49
6	-16141-82	32377-63	32609-96
7	-16109-77	32329-54	32601-42
8	-16076-89	32279-77	32591-19
9	-16039-66	32221-33	32572-29
10	-16015-29	32188-59	32579-09

Table S1. Likelihood-based model statistics for LCMMs fitted to faecal calprotectin data across 2–10 clusters using the chosen model specification. Boldface font indicates optimal values.

Clusters	Maximum log- likelihood	AIC	BIC
2	-15451-41	30932-82	31015-57
3	-15314-76	30675-52	30802-40
4	-15240-15	30542-29	30713-30
5	-15173-04	30424-09	30639-23
6	-15106-25	30306-50	30565-78
7	-15051-43	30212-86	30516-27
8	-15016-96	30159-91	30507-45
9	-15014-76	30171-53	30563-20
10	-15014-40	30186-81	30622-61

Table S2. Likelihood-based model statistics for LCMMs fitted to processed CRP data across 2-10 clusters using the chosen model specification. Boldface font indicates optimal values.

Supplementary material for Constantine-Cooke and Vestergaard et al.

Nathan Constantine-Cooke^{1, 2}, Marie Vibeke Vestergaard³, Karla Monterrubio-Gómez^{1, 2}, and Catalina A. Vallejos²

 $^{^{1}}$ Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

²MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

³Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Supplemental Note 1: Data definitions

1.1 Lothian IBD Registry

Additional phenotyping (at diagnosis)

When available, additional phenotyping information (at diagnosis) was manually extrated by the clinical team from electronic healthcare records (TrakCare; InterSystems, Cambridge, MA). For CD subjects, the following information was extracted:

• Smoking: recorded as a binary (yes/no) variable.

• Montreal location:

- L1 (Ileal): limited to the ileum, the final segment of the small intestine.
- L2 (Colonic): limited to the colon/large intestine.
- L3 (Ileocolonic): inflammation is present in both the ileum and colon.

• Montreal behaviour:

- B1 (Inflammatory): non-stricturing and non-penetrating
- B2 (Stricturing): where the formation of fibrosis leads to the narrowing of the intestine.
- B3 (Penetrating): where the inflammation causes the formation of fistulas or abscesses.

Due to small numbers, B2 and B3 are merged into a single group (complicated CD) when analysing Montreal behaviour.

- Upper GI inflammation (L4): whether any gastrointestinal inflammation is detected further up than the ileum. Usually, upper inflammation is considered a modifier for Montreal location. Recorded as a binary (yes/no) variable. L4 was missing for a high proportion of subjects. This is because the required investigations are only carried out where upper GI inflammation is suspected. As such, we have manually mapped missing L4 values as "No" (i.e. no upper GI inflammation for the associated patients).
- **Perianal disease**: considered a modifier for Montreal behaviour and is a severe complication of Crohn's disease involving inflammation around the anus. Recorded as a binary (yes/no) variable.

For UC subjects, the following additional phenotyping information was considered:

- Smoking: recorded as a binary (yes/no) variable.
- Montreal extent:
 - E1 (Ulcerative proctitis): limited to the rectum.
 - E2 (left sided colitis): inflammation is present in the rectum, the sigmoid colon, and possibly the descending colon.
 - E3 (extensive colitis): inflammation extends beyond the splenic flexure.

List of advanced therapies relevant for IBD management

The following biologics and small molecules were considered to be advanced therapies relevant for the treatment of IBD. All other advanced therapies were ignored. If one of these advanced therapies were prescribed for a condition other than IBD, for example for rheumatoid arthritis, then these treatments were still considered given they are known to modify IBD outcomes. Only prescriptions given within the observation period (seven years since diagnosis) were considered.

- Adalimumab
- Certolizumab
- Golimumab
- Infliximab
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab

1.2 National Danish registry data

Diagnosis adjudication

Subjects with IBD were defined as either

- 1. Having two different secondary care interactions linked to an ICD-10 IBD code (see Table 1.2) within a two year period, and/or
- 2. Two inpatient interactions assigned an IBD code (no period requirement).

If a subject meets only the first criterion, the first IBD secondary care interaction is used as the date of diagnosis. If a subject only meets the second criterion, then the date of the first inpatient record is used. If a patient meets both criteria, the earliest date is

Patients were assigned an IBD subtype (either CD or UC) based on the majority of the ICD-10 codes. If there were an equal number of IBD subtype diagnoses, the latest diagnosis was used.

Table 1.2 details the registry and codes used to obtain the data for each of the variables used in the Danish component of the study.

Prescribing and surgery data

As additional prescribing data were available for the Danish cohort, plots exploring these data were produced. Advanced therapy and immunomodulator plots were generated as the cumulative number of unique treatments over time for each patient. For systemic corticosteroids, one treatment course was defined as 1500 mg with the cumulative number of treatment courses plotted. For major surgeries related to IBD, the cumulative number of surgeries were plotted. For confidentiality reasons, categories with < 5 individuals in at each time interval were merged with the category with one fewer treatment.

Variable	Definition and codes	Source
IBD-related hospital	ICD-10: K50, K51	Danish National Patient Reg-
interactions		istry
Biochemistry tests		The Danish nationwide Regis-
		ter of Laboratory Results for
CRP	NPU: NPU19748	Research
Fecal calprotectin	NPU: NPU19717, NPU26814	
Biologic therapies	NI O. NI 019717, NI 020014	Danish National Prescription
and small molecules		Registry
Infliximab	C_OPR: BOHJ18A1/	100810019
	BOHJ18A	
Adalimumab	C_OPR: BOHJ18A3	
Ustekinumab	C_OPR: BOHJ18B3	
Vedolizumab	C_OPR: BOHJ19H4	
Natalizumab	C_OPR: BOHJ26	
Certolizumab	C_OPR: BOHJ18A5	
Golimumab	C_OPR: BOHJ18A4	
Risankizumab	C_OPR: BOHJ19N1	
Tofacitinib	C_OPR: BOHJ28D	
Upadacitinib	C_OPR: BWHP107	B 11 W 1 1 B 1 1
Immunomodulators		Danish National Prescription Registry
Azathioprine	ATC: L04AX01; C_OPR: BWHB83	
Mercaptopurine	ATC: L01BB02	
Methotrexate	ATC: $L04AX03/L01BA01$;	
	C_OPR: BWHA115	
Systemic corticos-	ATC: H02AB01, H02AB02,	Danish National Prescription
${f teroids}$	H02AB04, H02AB06,	Registry
	H02AB07, H02AB08,	
IBD-related major	H02AB09	Danish National Dationt Da-
IBD-related major surgery		Danish National Patient Registry
Intestinal resections	NCSP: KJGB, KJFB (excl.	1501 y
incoma resections	KJFB10+13)	
Enteroenterostomy	NCSP: KJFC	
Enterostomy	NCSP: KJFF	
Colectomy	NCSP: KJFH	
Intestinal stricture-	NCSP: KJFA60, KJFA61,	
plasty	KJFA63	
Other local intestinal	NCSP: KJFA96, KJFA97	
surgery		
Other intestinal surgery	NCSP: KJFW	
Stenosis surgery with-		
out	NGGD TITE	
resection or adhesiolysis	NCSP: KJFL	

Table 1.1: For each variable used in the Danish analyses, the corresponding registry and codes used to obtain the data.

Supplemental Note 2: Processing of CRP measurements

Further processing was applied to CRP data to smooth out short-term fluctuations. In the LIBDR, measurements were grouped into intervals of t: [0, 0.5), [0.5, 1.5), [1.5, 2.5), [2.5, 3.5), [3.5, 4.5), [4.5, 5.5), [5.5, 7], where t = 0 (years) is the time of diagnosis. The median CRP for each interval was calculated for each subject and used as input for subsequent analyses. The centre of each interval was used as the corresponding observation time. The same approach was used for the Danish data, however intervals of t: [0, 0.5), [0.5, 1.5), [1.5, 2.5), [2.5, 3.5), [3.5, 5] were used instead to take into account the differences in follow-up between the cohorts.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

Supplemental Note 3: Latent class mixed model

Introduction

This note provides a formal definition of latent class mixed models (LCMMs)¹ and describes how the most appropriate model specifications were found.

All models were fit using the lcmm R package. In all cases, models were fit using a maximum of 24,000 Marquardt iterations and all other options left at the default settings. An automatic grid search approach with 50 repetitions was used to attempt to avoid local maxima. All models converged as per default convergence criteria.

Formal definitions

The LCMM consists of two sub-models. A longitudinal sub-model and a class assignment sub-model. The former will be introduced before the latter.

Longitudinal sub-model

We assume a population of N individuals is heterogeneous and composed of G latent classes (or clusters): each characterised by a distinct mean profile of a marker of disease activity (in logarithmic scale) across time. We assume each subject i has a vector of repeated measurements of length n_i , allowing the number of measurements to differ across subjects. A random effects specification is used to capture intra-individual correlation in measurements. We allow each subject i to belong to only one latent class and introduce a discrete random variable c_i which is equal to g if subject i belongs to the latent class g, where $g = 1, \ldots, G$.

The logarithm of the biomarker measurement (FC or CRP) for the *i*th subject taken at time t_{ij} is denoted by Y_{ij} . Given that the subject *i* belongs to class *g*, the latter is modelled using a latent class mixed model LCMM:

$$Y_{ij}|_{c_i=g} = \mathbf{X}(t_{ij})'\beta_g + u_{ig} + \epsilon_{ij}$$
(3.1)

where the vector of regression coefficients β_g capture class-specific fixed effects, u_{ig} denote random effects distributed such that $u_{ig} \sim \mathcal{N}(0, \sigma_u^2)$ (we assume the variance σ_u^2 is shared across classes, but a more general form of the model allows for class-specific variance). In our analysis, we assume a single random effect (intercept) u_{ig} to account for correlation between longitudinal observations collected for the same individual. Finally, ϵ_{ij} indicates an independently distributed Gaussian error term with zero mean and variance σ_{ϵ}^2 .

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

Class membership sub-model

The probability of $c_i = g$ is given as a class-specific probability and is described by a multinomial logistic model:

$$P\left(c_{i}=g\right) = \frac{e^{\mathbf{X}_{ci}^{\top}\xi_{g}}}{\sum_{l=1}^{G} e^{\mathbf{X}_{ci}^{\top}\xi_{g}}},$$
(3.2)

where \mathbf{X}_{ci} is a vector of covariates and ξ_g is a vector of parameters whose first element corresponds to a class-specific intercept. For identifiability, the intercept associated to class G is assumed to be equal to zero. Note that the covariates in Equation (3.2) do not need to match those used in the longitudinal model. In our analysis, IBD type (CD, UC or IBDU for the LIBDR cohort; CD or UC for the Danish data) was included as a covariate in this model.

Posterior probabilities of class assignment

After inferring all model parameters, posterior class-membership probabilities for each subject are given by:

$$\hat{\pi}_{ig}^{Y} = P(c_i = g | \mathbf{Y}_i, \mathbf{X}(t_i), \hat{\theta}_G) = \frac{\hat{\pi}_{ig} \phi_{ig}(\mathbf{Y}_i | c_i = g, \hat{\theta}_G)}{\sum_{l=1}^{G} \hat{\pi}_{il} \phi_{il}(\mathbf{Y}_i | c_i = l, \hat{\theta}_G)}$$
(3.3)

where \mathbf{Y}_i denotes a vector of length n_i containing all longitudinal measurements recorded for subject i, $\mathbf{X}(t_i)$ is a matrix $(n_i \times 4)$ comprised of all the corresponding time-dependent covariates for subject i, $\hat{\theta}_G$ denotes the estimates obtained for all model parameters $(\beta_1, \ldots, \beta_G, \sigma_u^2, \sigma_{\epsilon}^2, \xi_1, \ldots, \xi_G)$ and $\hat{\pi}_{ig}$ corresponds to Equation (3.2) evaluated on $\hat{\theta}_G$. Finally, $\phi_{ig}(\mathbf{Y}_i|c_i = g, \hat{\theta}_G)$ denotes a multivariate normal density function with mean $\mathbf{X}(t_i)\hat{\beta}_g$ and variance covariance $\sigma_u^2\mathbf{X}(t_i)\mathbf{X}(t_i)' + \hat{\sigma}_{\epsilon}^2I_{n_i}$, where I_{n_i} denotes an identify matrix with dimension n_i .

Fixed effects specified as natural cubic splines

The vector of time-dependent covariates $\mathbf{X}(t)$ (see Equation (3.1)) was defined using an intercept term and natural cubic splines (NCS)² to capture non-linear dependency between observations and time. The NCS were calculated as a pre-processing step prior to estimating the model in Equation (3.1) using the ns() function of the splines R library³. Knots were located at quantiles of measurement times across all measurements.

To determine the most appropriate number of interior knots for the LIBDR cohort, LCMMs with six clusters were fitted to the LIBDR FC data assuming two to four knots. Visual inspection, Akaike information criterion (AIC), and Bayesian information criterion (BIC) were used to determine the most appropriate NCS specification, which was then used to fit the models used in the main analysis.

The optimal AIC was reported for the NCS model with four interior knots whilst BIC favoured the three-knot specification (Table 3.1). However, visual inspection of the

four-knot specification appeared to result in overfitting of the data (Figure 3.1). As such, the three-knot approach was used to specify the fixed effects of the longitudinal sub-model for all further FC and CRP modelling in the LIBDR cohort. As such, the time-dependent covarite vector was defined as $\mathbf{X}(t) = (1, X_1(t), X_2(t), X_3(t), X_4(t))'$ (the first element ensures the model includes an intercept term).

A similar approach was used to define the number of knots when analysing the Danish data. Two knots were chosen for both FC and CRP analyses.

Specification	Maximum log-likelihood	AIC	BIC
2 Knots	-19766.31	39614.61	39823.41
3 Knots	-19615.33	39324.67	39564.02
4 Knots	-19604.65	39315.30	39585.21

Table 3.1: Likelihood-based model statistics for LCMMs assuming six clusters with varying specifications for the fixed effects of the longitudinal sub-model. The models considered used natural cubic splines with varying knots. Boldface font indicates optimal values.




Figure 3.1: Cluster trajectories of FC for a LCMM using natural cubic splines with 4 knots. Vertical teal lines indicate knot locations. Dotted horizontal lines indicate $\log(250\mu g/g)$ FC which is commonly used as a cutoff for disease activity.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Supplemental Note 4: Software versions

As LIBDR and Danish analyses were conducted on separate computational platforms, the software versions differed.

4.1 Lothian IBD Registry

R (v. $4\cdot4\cdot2$),³ extended using the lcmm (v. $2\cdot1\cdot0$),¹ ggalluvial (v. $0\cdot12\cdot5$),⁴ nnet (v. $7\cdot3\cdot19$),⁵ and datefixR (v. $1\cdot7\cdot0$)⁶ packages, was used. Analytical reports have been generated using the Quarto scientific publishing system (v. $1\cdot4\cdot551$) and are hosted online (https://vallejosgroup.github.io/IBD-Inflammatory-Patterns/). An R package, libdr (v. $1\cdot1\cdot0$), has also been produced, supporting the reuse of our R code with other datasets.

4.2 National Danish registry data

R (v. 4·4·0) extended using the lcmm (2·1·0), ggalluvial 0·12·5, and nnet 7·3·19 packages was used for the Danish analyses. The R code is shared in the VallejosGroup/IBD-Inflammatory-Patterns GitHub repository under the source/dk directory.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Bibliography

- [1] Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using latent classes and latent processes: The R package lcmm. *J Stat Softw* 2017; 78(2): 1–56. doi: 10.18637/jss.v078.i02
- [2] Hastie T, Tibshirani R, Friedman J. *The Elements of Statistical Learning*. Springer Series in StatisticsNew York, NY: Springer . 2009
- [3] R Core Team . R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing . 2022.
- [4] Brunson JC. ggalluvial: layered grammar for alluvial plots. *J Open Source Softw* 2020; 5(49): 2017. doi: 10.21105/joss.02017
- [5] Venables WN, Ripley BD. Modern applied statistics with S. New York: Springer. fourth ed. 2002.
- [6] Constantine-Cooke N. datefixR: fix really messy dates in R. https://CRAN.R-project.org/package=datefixR; 2024